Krebs Biochemicals & Industries Share Price

Krebs Biochem

CMP as on 20-May-22 15:29

₹ 130.00
6.15 4.97%

Open

₹ 128.00

Turnover (lac)

₹ 17

Prev. Close

₹ 123.85

Day's Vol (shares)

₹ 12,786

Day's Range (₹)

₹ 125.00
₹ 130.95

CMP as on20-May-22 15:18

₹ 129.50
7 5.71%

Open

₹ 129.80

Turnover (lac)

₹ 11

Prev. Close

₹ 122.50

Day's Vol (shares)

₹ 412

Day's Range

₹ 127.70
₹ 129.80

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 05-Feb-2022 - -
KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2022 inter alia to consider and approve We refer to the above-mentioned subject we herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Saturday 12th February 2022 to transact inter alia the following: 1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter and Nine months ended 31st December 2021. 2. Any other matter with the permission of the Chair. Further in connection to the above trading window for dealing in shares of the Company was closed for the designated persons connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations 2015 as amended from 1st January 2022 and shall re-open 48 hours after the declaration of results. The Board of Directors in their meeting held on 12th February, 2022 have inter alia considered and approved the unaudited financial results for the quarter and nine months ended 31st December, 2021 and taken on record the limited review report issued by the Statutory Auditors of the Company Unaudited financial results as approved by the Board of Directors for the quarter and three months ended 31st December, 2021 along with limited review report given by the Statutory Auditors (As Per BSE Announcement Dated on 12.02.2022) Pursuant to Regulation 30 read with Schedule III Part A Para A of SEBI Listing Regulations, we are herewith enclosing the copies of newspaper advertisement published in Financial Express (English) and Praja Shakti (Telugu), relating to the unaudited financial results for the quarter and nine months ended 31st December 2021 approved by the Board of Directors in their meeting held on 12th February 2022 through Video Conferencing. (As Per BSE Announcement dated on 15.02.2022)
Board Meeting - 30-Dec-2021 - -
we herewith intimate to the Exchange that the Board of Directors at its meeting held on Thursday, the 30th December, 2021 has approved the allotment of 1,00,00,000, Redeemable Non-Convertible Non-Cumulative Preference Shares (RNNCPS) of Rs. 100/ each aggregating to Rs.100 crores, on private placement basis to M/s IPCA Laboratories Limited, a promoter group company.
Board Meeting - 02-Nov-2021 - -
Quarterly Results Quick results for the quarter and half year ended 30th September, 2021 along with the Limited Review Report thereon (Enclosed herewith) as approved by the Board of Directors at their meeting held on 9th November, 2021. Pursuant to the regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board of Directors in their meeting held on 9th November, 2021 have based on the recommendation of the Nomination and Remuneration Committee had :- 1.Appointed Mr. Jitendra Shah (DIN: 09377846) as Additional Director, Non-Executive Category 2. Resignation of Mr. E J Babu (DIN: 06759124), as Director .We further confirm that there is no other material reason for his resignation other than those provided herewith. (As Per BSE Announcement dated on 09.11.2021) Pursuant to Regulation 30 read with Schedule III Part A Para A of SEBI Listing Regulations, we are herewith enclosing the copies of newspaper advertisement published in Financial Express (English) and Praja Shakti (Telugu), relating to the un audited financial results for the quarter and half year ended 30th September, 2021 approved by the Board of Directors in their meeting held on 9th November, 2021 through Video Conferencing. (As Per BSE Announcement Dated on 10/11/2021)
Board Meeting - 18-Oct-2021 - -
Preferential Issue of shares & Increase in Authorised Capital With reference to the above captioned subject, we herewith intimate to the Exchange that the Board meeting held today i.e 22nd October, 2021 has been adjourned to 23rd October, 2021. It is further intimated that the board meeting commenced at 03.00 PM and has been adjourned to 23rd October, 2021. (As Per BSE Announcement dated on 22.10.2021) We herewith intimate inter alia regarding increase in Authorized share capital of the Company and issue/offer Preference shares. (As Per BSE Announcement dated on 23.10.2021)
Board Meeting - 22-Jul-2021 - -
KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2021 ,inter alia, to consider and approve We herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Tuesday, 30th July 2021 to transact, inter alia the following: 1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 30th June, 2021. 2. Any other matter with the permission of the Chair. This is for the information & records of the Exchange, Please. we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 30th July, 2021: (a) The Un-Audited financial results for the quarter ended 30th June, 2021 along with the Limited Review Report thereon (Enclosed herewith) have been adopted by the Board. (b) The Board has taken note of Resignation of Mr. Manish Jain, Director from the Board. (c) The Board has taken note of end of tenure of Mr. Avinash Ravi as Managing Director and accordingly Change in designation of Mr. Avinash Ravi from Managing Director to Non-Executive Director. (d) Appointment of Mr. Pabitra Bhattacharya as Additional Director and Managing Director of the Company subject to approval of members at the ensuing Annual General Meeting, whose Brief profile is attached herewith. We refer to the above mentioned subject, we herewith submit to the Exchange the quick results for the quarter ended 30th June, 2021 as approved by the Board of Directors at their meeting held on 30th July, 2021. (As per BSE Announcement Dated on 30/07/2021)
Board Meeting - 19-May-2021 - -
KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2021 ,inter alia, to consider and approve We herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Thursday, 27th May, 2021 to transact, inter alia the following: 1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter and year ended 31st March 2021. 2. Any other matter with the permission of the Chair. Further, in connection to the above, trading window for dealing in shares of the Company was closed for the designated persons, connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations, 2015 as amended, from 29th December 2020 and shall re-open 48 hours after the declaration of results. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [SEBI LODR Regulations], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 27th May, 2021: (a) The Audited financial results for the quarter and Year ended 31st March, 2021 along with the Auditor Report thereon (Enclosed herewith) have been adopted by the Board. we herewith submit to the Exchange the quick result for the quarter and year ended 31st March, 2021 as approved by the Board of Directors at their meeting held on 27th May, 2021. (As Per BSE Announcement dated on 27.05.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity